Oncology

Site of service has a major effect on the cost. Home infusion and oral formulations are challenging both hospital- and physician-based infusions.

Patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma were more likely to have a COVID-19 breakthrough infection.

Per episode saving of $297 during the first three years of the value-based care model were offset by $704 in payments for enhanced services to the 201 participating practices, study finds.

The studies conducted to support Verzenio’s most recent approval for the treatment of high-risk early breast cancer provided additional safety data.

The agency needs more time to review new information on the analytical method used.

Several generics of the cancer therapeutic are available.

Novartis’ Scemblix was approved for previously treated patients and for those who are resistant to TKI inhibitors.

Novatis is seeking approval for Kymriah in adult patients with advanced follicular lymphoma.

Cumulative spending on drugs without overall survival data was $1.8 billion in 2018 and surpassed that of drugs with such data.

Oncopeptides will close down its business units in the United States and Europe to focus exclusively on being a Sweden-based R&D company.

If a patient does not remain on the drug for at least three months due to effectiveness or tolerability, a significant portion of the drug cost will be refunded to Point32Health.

Tecentriq is the first cancer immunotherapy available for adjuvant treatment of non-small cell lung cancer (NSCLC).

Dr. Reddy’s received FDA approval for two strengths of lenalidomide for the treatment of patients with multiple myeloma.

Narsoplimab was under review at the FDA to treat a complication of stem cell transplants.

In COVID-19 news: An advisory committee recommends both J&J's and Moderna’s booster, Regeneron seeks full approved for its treatment and Merck seeks EUA for treatment. In cancer, the FDA approves Verzenio for early breast cancer, Keytruda for advanced cervical cancer, and Tecentriq in early nonsmall cell lung cancer.

This is the first anti-PD-1 combination approved for patients with persistent, recurrent or metastatic cervical cancer.

Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.

Pfizer officially seeks EUA for pediatric COVID vaccine, AstraZeneca seeks EU for COVID-19 prevention, J&J submits data for COVID-19 booster, a gene therapy is approved for leukemia, and Janssen submits Stelara for psoriatic arthritis in children.

Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.

Many states only have vaguely worded qualitative standards for network adequacy for cancer care. Others have quantitative standards based on distance or waiting time.

Talicia treats H. pylori infection, a risk factor for stomach cancer; Twirla is a hormonal contraceptive.

Tecartus is the first CAR T-cell therapy approved to treat adults with relapsed or refractory ALL.

Half of the 14 oncology indications approved in the second quarter were accelerated approvals.

This is the seventh approval for Erbitux and the only anti-EGFR antibody approved for this indication.

The PDUFA target action date for the FDA decision is Jan. 30, 2022.

The FDA assigned a Prescription Drug User Fee Act goal date of May 28, 2022.

Amgen’s Biosimilar Trend Report finds that biosimilars have been introduced at a price that is generally 15% to 37% lower than the reference product.

Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.

Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations.

This is the fourth approval for Jakafi, a JAK1/JAK2 inhibitor.